JP2023503167A5 - - Google Patents
Info
- Publication number
- JP2023503167A5 JP2023503167A5 JP2022530740A JP2022530740A JP2023503167A5 JP 2023503167 A5 JP2023503167 A5 JP 2023503167A5 JP 2022530740 A JP2022530740 A JP 2022530740A JP 2022530740 A JP2022530740 A JP 2022530740A JP 2023503167 A5 JP2023503167 A5 JP 2023503167A5
- Authority
- JP
- Japan
- Prior art keywords
- cancers
- dosage form
- unit dosage
- cancer
- sdi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940514P | 2019-11-26 | 2019-11-26 | |
| US62/940,514 | 2019-11-26 | ||
| US202063106530P | 2020-10-28 | 2020-10-28 | |
| US63/106,530 | 2020-10-28 | ||
| PCT/US2020/062116 WO2021108469A1 (en) | 2019-11-26 | 2020-11-25 | Ahr inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023503167A JP2023503167A (ja) | 2023-01-26 |
| JP2023503167A5 true JP2023503167A5 (enExample) | 2023-12-04 |
Family
ID=73856333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530740A Withdrawn JP2023503167A (ja) | 2019-11-26 | 2020-11-25 | Ａｈｒ阻害剤およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230026232A1 (enExample) |
| EP (1) | EP4065090A1 (enExample) |
| JP (1) | JP2023503167A (enExample) |
| KR (1) | KR20220125232A (enExample) |
| CN (1) | CN115279347A (enExample) |
| AU (1) | AU2020391451A1 (enExample) |
| BR (1) | BR112022010143A2 (enExample) |
| CA (1) | CA3159315A1 (enExample) |
| IL (1) | IL293325A (enExample) |
| MX (1) | MX2022006312A (enExample) |
| WO (1) | WO2021108469A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
| TW202421150A (zh) * | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| EP3774767B1 (en) * | 2018-04-05 | 2025-10-29 | Beth Israel Deaconess Medical Center, Inc. | Aryl hydrocarbon receptor modulators and uses thereof |
| KR20210151061A (ko) * | 2019-03-11 | 2021-12-13 | 피티씨 테라퓨틱스, 인크. | 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형 |
-
2020
- 2020-11-25 EP EP20828448.9A patent/EP4065090A1/en not_active Withdrawn
- 2020-11-25 KR KR1020227021773A patent/KR20220125232A/ko not_active Withdrawn
- 2020-11-25 US US17/779,893 patent/US20230026232A1/en not_active Abandoned
- 2020-11-25 IL IL293325A patent/IL293325A/en unknown
- 2020-11-25 BR BR112022010143A patent/BR112022010143A2/pt not_active Application Discontinuation
- 2020-11-25 MX MX2022006312A patent/MX2022006312A/es unknown
- 2020-11-25 WO PCT/US2020/062116 patent/WO2021108469A1/en not_active Ceased
- 2020-11-25 AU AU2020391451A patent/AU2020391451A1/en not_active Abandoned
- 2020-11-25 CA CA3159315A patent/CA3159315A1/en active Pending
- 2020-11-25 CN CN202080092187.6A patent/CN115279347A/zh not_active Withdrawn
- 2020-11-25 JP JP2022530740A patent/JP2023503167A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022121594A5 (enExample) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2023516291A5 (enExample) | ||
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| US11065240B2 (en) | Drug combinations to treat multiple myeloma | |
| JP2012522837A5 (enExample) | ||
| RU2734260C2 (ru) | Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием | |
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| TW201323864A (zh) | 定量癌症治療之方法 | |
| JP4852605B2 (ja) | 放射線治療増強剤 | |
| WO2019094053A1 (en) | Disulfiram and copper salt dosing regimen | |
| TW202342062A (zh) | 濱及西屈嘧啶(cedazuridine)之組合調配物 | |
| JP2006517195A5 (enExample) | ||
| JP5103170B2 (ja) | ピリジン誘導体を有効成分とする放射線治療増強剤 | |
| JP4956423B2 (ja) | 放射線治療増強剤 | |
| JP6937308B2 (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| JP6739275B2 (ja) | ゲフィチニブを有効成分とする医薬組成物 | |
| JP2020533368A5 (enExample) | ||
| JP2020090456A (ja) | エルロチニブを有効成分とする医薬錠剤 | |
| CA3010654C (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| JP2026510895A (ja) | 経口バイオアベイラビリティを向上させるための医薬組成物 | |
| JP2015199678A (ja) | ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2025506402A5 (enExample) | ||
| Keilholz et al. | 614 first-in-man dose escalation and pharmacokinetic study of CAP7. 1, a novel etoposide prodrug in adults with heavily pretreated solid tumors |